Share on Facebook
Share on Twitter
Share on LinkedIn

Johnson & Johnson (JNJ)’s Janssen unit pleaded guilty to misbranding its anti-psychotic medication Risperdal as part of a $2.2 billion settlement with U.S. prosecutors, the largest for a single drug.

The company, based in Titusville, New Jersey, entered the guilty plea today to one misdemeanor at a hearing before U.S. District Judge Timothy Savage in Philadelphia.

Click here to read more.